ZAMBON PHARMA PERFORMANCE IN 2010
In 2010 Zambon recorded total net revenues of € 464 million, the same as last year, despite the flu pathology which was weaker than in 2009.
This heavy impact on sales over the previous year was almost entirely set off by the good performance of the Gastro segment which recorded a 24% growth rate, by the positive contribution of Pain therapy products for an increase of 3% and by Toll Manufacturing which recorded a growth of 20% for a total figure equal to € 33 million.
Growth was also sustained by substantial development and consolidation in countries outside Europe and, in particular, by Brazil, Russia, Colombia and China.
The new launches and line extensions contributed to growth for an overall value of € 9 million.